NCT04049851View on ClinicalTrials.gov

Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 7, 2022

Primary Completion Date

July 22, 2023

Study Completion Date

July 22, 2023

Conditions
Onchocerciasis, OcularLoiasis
Interventions
DRUG

Moxidectin 2 MG Oral Tablet

One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.

DRUG

Ivermectin 3Mg Tab

3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.

DRUG

Placebo oral tablet

Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.

Trial Locations (1)

Unknown

Centre de recherche sur les filarioses et autres maladies tropicales (CRFilMT), Yaoundé

All Listed Sponsors
lead

Center for Research on Filariasis and Other Tropical Diseases, Cameroon

OTHER